Macquarie Group’s Biocept, Inc. BIOC Stock Holding History

Macquarie Group’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-28	Closed	-$7K	–	2143
2018 Q4	$7K	Buy	+28	New	+$14.1K	﹤0.01%	2019
2018 Q1	–	Sell	-1	Closed	-$8K	–	2433
2017 Q4	$8K	Buy	+1	New	+$7.91K	﹤0.01%	2319

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Macquarie Group's BIOC Position: Q1 2019 in Review

Macquarie Group sold out of Biocept, Inc. (BIOC) in Q1 2019, closing a stake of 28 shares — an estimated $7K sold.

Macquarie Group first reported a position in BIOC in Q4 2017 and held it in 2 quarters. The position peaked at $8K in Q4 2017. 17 funds tracked by Wall St. Rank hold BIOC as of Q1 2019.

Macquarie Group reported no remaining Biocept, Inc. position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 28 Biocept, Inc. shares in Q1 2019, an estimated $7K.
Macquarie Group first reported a position in Biocept, Inc. in Q4 2017 and held it in 2 quarters.
Macquarie Group's Biocept, Inc. position peaked at $8K in Q4 2017.
17 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.